Boston Scientific

Latest Headlines

Latest Headlines

Boston Scientific eyes FDA with new leads

Boston Scientific has launched a U.S. trial of two next-generation leads for defibrillators and pacemakers, working toward FDA approval after completing the first implant.

Boston Scientific scores FDA approval for a new crop of implantable cardiac devices

Boston Scientific won FDA approval for a new crop of implantable defibrillators and heart failure devices, helping the company move forward with sales and development of its cardiac rhythm management system.

Boston Scientific launches a new clinical trial of its deep brain stimulation device

Boston Scientific is ramping up neuromodulation efforts with a new clinical trial of its implantable deep brain stimulation device for patients with Parkinson's disease.

Boston Scientific eyes Israel in global marketing push

As part of its strategy to sell more products in foreign markets, Boston Scientific announced the signing of a distribution partnership agreement allowing Israel's Amos Gazit Ltd to market and sell its interventional cardiology, peripheral interventions, endoscopy and urology/women's health products.

Boston Scientific takes to Asia with its subcutaneous ICD

Boston Scientific has launched its much-hyped S-ICD in Asia, notching the first implant of the under-the-skin system in Hong Kong as it looks to expand the market for the device.

Boston Scientific touts promising trial data for its transcatheter heart valve

It's a crowded market for transcatheter aortic devices, and Boston Scientific is trying to get a leg up on the competition. The company is celebrating positive study results for its transcatheter aortic valve replacement, touting data that it hopes will set it apart from its market rivals.

California startup draws in a $32.6M Series A to advance its neuromodulation implant tech

Axonics Modulation Technologies got itself a $32.6 million Series A funding round that will help advance its implantable neuromodulation technology into human clinical studies to treat a variety of conditions.

The top companies in med tech: 2013 revenue results

In 2013, a number of outside forces hammered the med tech industry. While things could have been better, most of the top 10 companies in the sector still enjoyed moderate year-over-year revenue gains.

Boston Scientific bets on a big future for bare metal stents

Boston Scientific gained a CE mark for a new platinum bare metal stent to treat coronary artery disease.

The top 10 med tech M&A deals of 2013

Forget organic growth. In 2013, some of the biggest moves into new or expanded markets in the med tech world came through serious M&A activity. The top deals announced or closed in 2013 created...